SCHEMBL2928909

SCHEMBL2928909

CCN1CCN(c2ccc(OC)c(S(C)(=O)=O)c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM2B Q8NHM5 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TSHR P16473 2/20 0.47
POLB P06746 2/20 0.46
MAPK1 P28482 2/20 0.46
HSD17B10 Q99714 1/20 0.46
GAA P10253 2/20 0.46
RAD52 P43351 2/20 0.46
ALDH1A1 P00352 1/20 0.45
HTR6 P50406 3/20 0.44
DRD3 P35462 3/20 0.44
HRH3 Q9Y5N1 2/20 0.44
MAPT P10636 2/20 0.44
KDM4E B2RXH2 1/20 0.44
GFER P55789 1/20 0.44
DRD2 P14416 3/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2928872 0.90 DRD2 (0.57) SMN1; SMN2TSHRPOLBMAPK1HTR6
SCHEMBL2926804 0.87 DRD2 (0.51) SMN1; SMN2HSD17B10GAADRD3KDM4E
SCHEMBL2922399 0.85 TMEM97 (0.45) SMN1; SMN2TSHRPOLBMAPK1ALDH1A1
SCHEMBL7430034 0.83 DRD2 (0.51) SMN1; SMN2POLBHTR6DRD3DRD2
SCHEMBL2925539 0.81 SMN1; SMN2 (0.48) SMN1; SMN2TSHRPOLBMAPK1ALDH1A1
SCHEMBL5240099 0.81 HTR7 (0.58) SMN1; SMN2POLBGAARAD52ALDH1A1
SCHEMBL2929064 0.81 HTR6 (0.53) SMN1; SMN2MAPK1ALDH1A1HTR6KDM4E
SCHEMBL23102236 0.77 KDM4E (0.50) SMN1; SMN2POLBMAPK1GAARAD52
SCHEMBL1599674 0.77 PTPN7 (0.51) SMN1; SMN2POLBGAARAD52ALDH1A1
SCHEMBL1911999 0.76 GAA (0.59) SMN1; SMN2POLBMAPK1HSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE41315-E1 Modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DE) 2010-05-04 US disclosed
US-6924374-B2 Central nervous system disorders; psychological disorders A. CARLSSON RESEARCH AB (SE) 2005-08-02 US disclosed
EP-1419773-A2 4-Phenylpiperidine derivatives as modulators of dopamine neurotransmission A. Carlsson Research AB (SE) 2004-05-19 EP disclosed
US-20030004169-A1 Modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2003-01-02 US disclosed
EP-1240143-A1 NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION A. Carlsson Research AB (SE) 2002-09-18 EP disclosed
WO-2001046146-A1 NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION A. CARLSSON RESEARCH AB (SE) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004169-A1 Modulators of dopamine neurotransmission OPRD1, OPRK1, OPRM1 KDM2B 3705/4885SMN1; SMN2 904/4885TSHR 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.